We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 352

Judicial Review of Commissioner's Decision Refusing to Amend Priority Date Dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • March 1 2017

The Federal Court dismissed Bayer's application for judicial review of the Commissioner of Patents' decision refusing Bayer's request to amend the


Decision of Minister of Health Rejecting ANDS Upheld
  • Borden Ladner Gervais LLP
  • Canada
  • February 22 2017

Apotex sought judicial review of a decision of the Minister of Health that had the effect of rejecting its Abbreviated New Drug Submission (ANDS) for


Allegations of Invalidity Found Justified on the Basis of Obviousness
  • Borden Ladner Gervais LLP
  • Canada
  • February 15 2017

In this case, the Federal Court dismissed an application for an order of prohibition. The patent at issue claimed pharmaceutical formulations of


Unparticularized Allegations Made Pursuant to S. 53 Struck Without Leave to Amend
  • Borden Ladner Gervais LLP
  • Canada
  • February 1 2017

In this case, Apotex started an action to impeach Shire's patent relating to lisdexamfetamine dimesylate. Shire brought a motion to strike portions of


Court Dismisses Alexion's Appeals from Three Separate Orders
  • Borden Ladner Gervais LLP
  • Canada
  • February 1 2017

The Court dismissed Alexion's appeals concerning three separate Orders. The first appeal concerned Prothonotary Aalto's Order allowing the


Costs Awarded at the Higher End of Column IV, with Elevated Costs for Various Factors
  • Borden Ladner Gervais LLP
  • Canada
  • February 1 2017

In this decision on costs, the Court award costs calculated at the top of column IV of Tariff B to the Plaintiff for its successful impeachment action


Industry Updates - Intellectual Property Weekly Abstracts - Week of January 16, 2017
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

In January 2017, sections 17.07 and 17.08 in chapter 17 of the Manual of Patent Office Practice (MOPOP) were revised to reflect antibody practice. A


Application for Prohibition Granted for Generic Version of Concerta
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

The Court granted Janssen's application prohibiting the Minister of Health from issuing an NOC to Actavis for its generic version of Concerta. The


Patent Validity and Infringement Upheld on Appeal; Limitation Period in Patent Act not Necessarily Applicable to Old Act Patents
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

In this case, the FCA considered an appeal and cross-appeal of a decision relating to omeprazole. The trial decision can be found here (2015 FC 322


Supreme Court Updates - Intellectual Property Weekly Abstracts - Week of January 16, 2017
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

The Supreme Court of Canada announced that judgment in this application for leave to appeal will be delivered on Thursday, January 19, 2017. The